RAPS Learning Portal will be under maintenance on 12 June 2026 between 10 PM - 12 AM ET. Learning Portal functionality and profile access may be unavailable during this window.
We apologize for any inconvenience caused during this time.
FDA finalizes two more safety and performance based pathway guidances
The US Food and Drug Administration (FDA) on Tuesday published two more final safety and performance based pathway guidances for medical devices on the heels of releasing two other guidances under the pathway last week. The newly finalized guidances provide recommendations for device makers to follow the less burdensome pathway for facet screw systems and denture base resins.
On 12 April, the agency published guidances that allow certain denture base resins and facet screw systems to use the optional pathway, which allows companies to demonstrate substantial equivalence by meeting established safety and performance criteria, rather than via direct comparison testing.
“The facet screw systems that fall within the scope of this guidance document are intended for bilateral immobilization of facet joints to stabilize the spine as an aid to fusion,” the agency notes. “The optional washer components are intended for use with the facet screw to aid in load distribution at the screw head/bone interface.”
Similarly, the FDA states that its Denture Base Resins – Performance Criteria for Safety and Performance Based Pathway guidance covers prosthetic devices that use denture rebasing resin composed of materials such as methyl methacrylate and are intended to reline denture surfaces that contact tissue, to repair a fractured denture, or to form a new denture base. The agency also notes that the devices are not for over-the-counter use.
“These devices are intended for the fabrication of patient-specific denture bases for full or partial dentures,” the agency added.
Both guidances list various performance testing criteria that should be met, including mechanical testing and biocompatibility evaluation, while the facet screw systems guidance also lists sterilization and reprocessing validation and the denture base resin guidance includes a section on additive manufacturing, or 3D-printing, considerations.
The Pharmaceuticals and Medical Devices Agency (PMDA) published guidance on using a weight of evidence (WOE) approach to assessing the toxicity of monoclonal antibodies in Japan.
Industry groups have asked the US Food and Drug Administration (FDA) to provide more clarity about its regulatory approach to digital health technologies (DHTs), as well as for greater flexibility in their use in clinical trials.